JUN 20, 2019 12:00 PM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Bringing Precision Medicine to Veterinary Oncology

SPONSORED BY: Twist Bioscience
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers

Abstract:

The long term goal of our collaborative effort is to bring precision medicine to the practice of veterinary oncology, using the wealth of genomic data gathered in human cancers as a roadmap.   We pioneered the concept of precision medicine in a common but deadly canine tumor, hemangiosarcoma (HSA), whose equivalent in human is angiosarcoma (AS), a rare yet highly fatal disease. We performed whole exome sequencing to investigate the mutation landscape of HSA and identified candidate driver mutations and therapeutic targets (Wang G, etc, 2017). Based on findings from exome sequencing and genomics data on homologous human disease (AS), I developed an amplicon-based targeted resequencing panel, HSA-panel, which allows genotyping of canine HSA at high coverage, high specificity and sensitivity and yet cost-effective. Together, the discovery sequencing and targeted panel sequencing identified candidate driver mutations in more than 90% patients’ samples, suggesting high diagnostic utility (Wang G, etc, unpublished). More importantly, the two most common driver mutations, present in more than 75% of HSA cases (Wang G, etc, unpublished), are great therapeutic targets suitable for pharmacological intervention, with specific inhibitors already in clinical use in humans. These findings offer us opportunities to perform clinical trials of targeted therapies in canine hemangiosarcoma, which may lead to novel and effective treatment options for canine disease, as well as to inform trial design for similar human disease. Our study in hemangiosarcoma serves as proof-of-concept to enable precision medicine in other canine cancers. To this end, I constructed a capture-based comprehensive canine cancer panel, which detects a wide range of mutations in 282 genes known to drive cancer development and covers a total target region of 1.4 mb in canine genome. Our goal is to identify driver mutations and clinically actionable biomarkers in all common canine cancers, to arm veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict treatment response, ultimately enabling precision medicine in canine oncology. 

Learning Objectives: 

1. You will learn about the mutation landscape of a common yet deadly canine tumor, hemangiosarcoma, through whole exome sequencing and targeted panel resequencing
2. You will learn about the identified candidate driver mutations and therapeutic targets in over 75% of cases


Show Resources
You May Also Like
MAY 16, 2019 04:00 PM CEST
C.E. CREDITS
MAY 16, 2019 04:00 PM CEST
DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
FEB 26, 2019 09:00 AM PST
C.E. CREDITS
FEB 26, 2019 09:00 AM PST
DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
MAR 26, 2019 02:00 PM PDT
C.E. CREDITS
MAR 26, 2019 02:00 PM PDT
DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
JUN 05, 2019 05:00 PM CEST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUN 05, 2019 05:00 PM CEST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
MAR 05, 2019 09:00 AM PST
C.E. CREDITS
MAR 05, 2019 09:00 AM PST
DATE:  March 5, 2019TIME:  09:00am PST, 12:00pm EST MicroRNA(miRNA) are short non-coding single stranded RNA molecules that regulate gene expression at the post tran...
MAY 21, 2019 07:00 AM PDT
C.E. CREDITS
MAY 21, 2019 07:00 AM PDT
DATE: May 21, 2019TIMEL 7:00am PT, 10:00am ET Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based functional studies in T cells could prioriti...
Loading Comments...
Show Resources
Event Countdown
  • 0 Days
  • 0 Hours
  • 0 Minutes
  • 0 Seconds